Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11619922 | 0.93 | PTPN1 (0.57) | PTPN1SMN1; SMN2RAB9AHCAR2KDM4E | |
| SCHEMBL212382 | 0.85 | RAB9A (0.68) | PTPN1SMN1; SMN2RAB9AHCAR2KDM4E | |
| SCHEMBL8880032 | 0.84 | HCAR2 (0.55) | PTPN1SMN1; SMN2RAB9AHCAR2RXFP1 | |
| SCHEMBL3611504 | 0.84 | PTPN1 (0.57) | PTPN1SMN1; SMN2RAB9AMEN1ALDH1A1 | |
| SCHEMBL3989188 | 0.84 | LMNA (0.51) | PTPN1SMN1; SMN2RAB9AMCL1KDM4E | |
| SCHEMBL3101558 | 0.84 | PTPN1 (0.64) | PTPN1SMN1; SMN2RAB9AHCAR2KDM4E | |
| Hydrochloric Acid SCHEMBL8880218 | 0.84 | RAB9A (0.66) | PTPN1SMN1; SMN2RAB9AHCAR2KDM4E | |
| SCHEMBL7999942 | 0.83 | PTPN1 (0.50) | PTPN1SMN1; SMN2RAB9AHCAR2KDM4E | |
| Hydrochloric Acid SCHEMBL8878911 | 0.83 | HCAR2 (0.53) | PTPN1SMN1; SMN2RAB9AHCAR2RXFP1 | |
| Hydrochloric Acid SCHEMBL6822320 | 0.83 | PTPN1 (0.56) | PTPN1SMN1; SMN2RAB9AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | claimed |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | IPS HEART | 2021-02-25 | — | — | US | disclosed |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | IPS HEART | 2018-09-27 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | PTPN1 1441/4885SMN1; SMN2 1142/4885RAB9A 2721/4885 |
| US-20180273906-A1 | MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS | EXOSC9, EXOSC5, EXOSC4 | PTPN1 3314/4885SMN1; SMN2 14/4885RAB9A 334/4885 |
| US-20210054344-A1 | CPC EXOSOMES MIRNA373 COMBINATION THERAPIES | EXOSC5, UTRN, EXOSC4 | PTPN1 3176/4885SMN1; SMN2 13/4885RAB9A 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.